Keystone Financial Group Sells 1,450 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Keystone Financial Group lessened its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 3.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,154 shares of the company’s stock after selling 1,450 shares during the period. Keystone Financial Group’s holdings in Teva Pharmaceutical Industries were worth $885,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $29,000. Wilmington Savings Fund Society FSB purchased a new position in Teva Pharmaceutical Industries in the third quarter worth about $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $66,000. IFP Advisors Inc increased its position in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock worth $96,000 after purchasing an additional 949 shares during the period. Institutional investors own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEVA. Barclays reduced their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. UBS Group reduced their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Finally, Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $13.42 on Monday. The stock has a 50-day moving average price of $15.79 and a 200 day moving average price of $17.82. The stock has a market capitalization of $15.22 billion, a P/E ratio of -9.26, a P/E/G ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.